daratumumab
Janssen
['mmsm']
#asco22 oral session #mmsm ifm 2008-04 (i like this one-nice results-high risk)
phase ii, high risk
dara-krd. some issues with stem cell collection yield. so early collection is imp pfs is impressive 18mo pfs:92%, nice ttt strategy in high risk pt (unmet need) 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities. No COI